- •Human mesenchymal stem cells have anti-inflammatory and immunomodulatory properties.
- •Preclinical models of CF show mesenchymal stem cells attenuate pulmonary inflammation.
- •Mesenchymal stem cells were safe and well-tolerated in this phase 1 clinical trial.
Mesenchymal stem cells are of particular interest in cystic fibrosis (CF) as a potential therapeutic. Data from pre-clinical studies suggest that allogeneic bone marrow-derived human mesenchymal stem cells (hMSCs) may provide a new therapeutic treatment for CF lung disease by attenuating pulmonary inflammation while decreasing bacterial growth and enhancing antibiotic efficacy.
Fifteen adults with CF were enrolled in a phase 1 dose-escalation trial of a single intravenous infusion of hMSCs derived from bone marrow aspirates obtained from a single pre-clinically validated healthy volunteer donor. The study employed a 3+3 dose escalation design with subjects receiving a single, intravenous dose of either 1×106, 3×106, or 5×106 hMSCs/kg. Subjects were monitored inpatient for 24 hours and by outpatient visits and telephone calls for 12 months after the infusion. Safety and tolerability were evaluated by monitoring symptoms, patient reported outcome questionnaires, adverse events (AEs), physical exam findings, spirometry, and analyses of safety laboratories. Preliminary evidence for potential efficacy using inflammatory markers in the blood and sputum were also evaluated.
No dose-limiting toxicities, deaths or life-threatening adverse events were observed. Most AEs and serious adverse events (SAEs) were consistent with underlying CF. Vital signs, physical exam findings, spirometry and safety laboratory results showed no significant change from baseline. No trends over time were seen in serum or sputum inflammatory markers nor with clinical spirometry.
Allogeneic hMSC intravenous infusions were safe and well-tolerated in this phase 1 study and warrant additional clinical testing as a potential therapeutic for CF lung disease.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Cystic Fibrosis
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Cystic fibrosis.Am J Respir Crit Care Med. 1996; 154: 1229-1256
- Inflammation and its genesis in cystic fibrosis.Pediatr Pulmonol. 2015; 50: S39-S56
- Dysregulated cytokine production in human cystic fibrosis bronchial epithelial cells.Inflammation. 2001; 25: 145-155
- Proinflammatory cytokine responses to P. aeruginosa infection in human airway epithelial cell lines.Am J Physiol Lung Cell Mol Physiol. 2001; 280: L493-L502
- Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients.Am J Respir Crit Care Med. 1999; 160: 186-191
- Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis.Pediatr Pulmonol. 2001; 32: 356-366
- Infection is not required for mucoinflammatory lung disease in CFTR-knockout ferrets.Am J Respir Crit Care Med. 2018; 197: 1308-1318
- Inflammation in cystic fibrosis: an update.Pediatr Pulmonol. 2018; 53: S30-S50
- Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del Allele.N Engl J Med. 2019; 381: 1809-1819
- Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.Am J Respir Crit Care Med. 2014; 190: 175-184
- Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections.Am J Respir Crit Care Med. 2017; 195: 1617-1628
- Six-year follow-up of ivacaftro-treated subjects with CFTR-G551D: an update on the Dublin cohort.Pediatr Pulmonol. 2019; 54: 334
- Mesenchymal stem cell therapy in lung disorders: pathogenesis of lung diseases and mechanism of action of mesenchymal stem cell.Exp Lung Res. 2013; 39: 315-327
- Lights and shadows in the use of mesenchymal stem cells in lung inflammation, a poorly investigated topic in cystic fibrosis.Cells. 2019; 9
- Optimization of human mesenchymal stem cells for rheumatoid arthritis: implications for improved therapeutic outcomes.ACR Open Rheumatol. 2021;
- Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?.Blood Rev. 2021; 46100742
- Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37.Stem Cells. 2010; 28: 2229-2238
- Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine.Exp Mol Med. 2013; 45: e54
- Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells.Stem Cells Transl Med. 2021; 10: 1288-1303
- Cell based therapy aides in infection and inflammation resolution in the murine model of cystic fibrosis lung disease.Stem Cell Discovery. 2013; 3: 139-153
- Antimicrobial properties of mesenchymal stem cells: therapeutic potential for cystic fibrosis infection, and treatment.Stem Cells Int. 2016; 20165303048
- Enhancing cystic fibrosis immune regulation.Front Pharmacol. 2021; 12573065
- Mesenchymal stem cell soluble mediators and cystic fibrosis.J Stem Cell Res Ther. 2017; 7
- Donor-defined mesenchymal stem cell antimicrobial potency against nontuberculous mycobacterium.Stem Cells Transl Med. 2021; 10: 1202-1216
- Consensus International Council for Commonality in Blood Banking Automation-International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells.Cytotherapy. 2021; 23: 1060-1063
- Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The pulmozyme study group.N Engl J Med. 1994; 331: 637-642
- Differential effects of the cystic fibrosis lung inflammatory environment on mesenchymal stromal cells.Am J Physiol Lung Cell Mol Physiol. 2020; 319: L908-L925
- Biological considerations in scaling up therapeutic cell manufacturing.Front Pharmacol. 2020; 11: 654
Published online: December 20, 2022
Accepted: December 3, 2022
Received in revised form: November 25, 2022
Received: August 1, 2022
Publication stageIn Press Corrected Proof
© 2022 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.